Compare Novo Nordisk A/S (NVO) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while YieldMax Universe Fund of Option Income ETFs trades at $7.72. The key difference: Novo Nordisk A/S pays a 3.63% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NVO | YMAX | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $71.70 | $14.00 |
52-Week Low | $35.29 | $7.51 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
